Wall Street Zen upgraded shares of Monopar Therapeutics (NASDAQ:MNPR – Free Report) from a sell rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.
A number of other analysts have also recently commented on MNPR. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Zacks Research cut Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. Morgan Stanley reiterated an “overweight” rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research note on Monday, August 17th. BTIG Research increased their target price on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a research note on Thursday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Monopar Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $120.08.
View Our Latest Stock Analysis on MNPR
Monopar Therapeutics Price Performance
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.02. Equities research analysts expect that Monopar Therapeutics will post -2.94 EPS for the current year.
Insider Buying and Selling
In other Monopar Therapeutics news, Director Kim Tsuchimoto sold 4,090 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total transaction of $455,585.10. Following the completion of the transaction, the director owned 7,396 shares in the company, valued at $823,840.44. This trade represents a 35.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of Monopar Therapeutics stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total value of $351,181.34. Following the completion of the sale, the director directly owned 23,751 shares in the company, valued at approximately $2,654,649.27. The trade was a 11.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Monopar Therapeutics
Several large investors have recently bought and sold shares of MNPR. Siren L.L.C. lifted its position in Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after purchasing an additional 57,820 shares during the last quarter. ADAR1 Capital Management LLC grew its stake in shares of Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after buying an additional 30,370 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Monopar Therapeutics by 21.2% in the 1st quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock worth $4,307,000 after buying an additional 13,761 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of Monopar Therapeutics during the 1st quarter valued at about $3,458,000. Finally, Bank of America Corp DE raised its position in shares of Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after buying an additional 53,336 shares in the last quarter. Institutional investors own 1.83% of the company’s stock.
Monopar Therapeutics Company Profile
Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.
The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.
Featured Articles
- Five stocks we like better than Monopar Therapeutics
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
